CY1111961T1 - Φαρμακοτεχνικες μορφες που περιλαμβανουν μετφορμινη και φιμπρατη και μεθοδοι για ληψη αυτων - Google Patents

Φαρμακοτεχνικες μορφες που περιλαμβανουν μετφορμινη και φιμπρατη και μεθοδοι για ληψη αυτων

Info

Publication number
CY1111961T1
CY1111961T1 CY20111100999T CY111100999T CY1111961T1 CY 1111961 T1 CY1111961 T1 CY 1111961T1 CY 20111100999 T CY20111100999 T CY 20111100999T CY 111100999 T CY111100999 T CY 111100999T CY 1111961 T1 CY1111961 T1 CY 1111961T1
Authority
CY
Cyprus
Prior art keywords
fiberty
taking
methods
forms including
pharmaceutical forms
Prior art date
Application number
CY20111100999T
Other languages
English (en)
Inventor
Gordon Dawson
Carthy Leonard Mc
Original Assignee
Fournier Laboratories Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Laboratories Ireland Limited filed Critical Fournier Laboratories Ireland Limited
Publication of CY1111961T1 publication Critical patent/CY1111961T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά προϊόντα κοκκοποίησης που περιλαμβάνουν σωματίδια μετφορμίνης και σωματίδια μιας φιμπράτης. Η εφεύρεση περαιτέρω αφορά φαρμακευτικές συνθέσεις που περιέχουν τέτοια προϊόντα κοκκοποίησης. Η εφεύρεση επίσης αφορά μεθόδους για παρασκευή των εν λόγω προϊόντων κοκκοποίησης και των εν λόγω φαρμακευτικών συνθέσεων.
CY20111100999T 2004-01-23 2011-10-21 Φαρμακοτεχνικες μορφες που περιλαμβανουν μετφορμινη και φιμπρατη και μεθοδοι για ληψη αυτων CY1111961T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04001499A EP1559419A1 (en) 2004-01-23 2004-01-23 Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
EP05715343A EP1706102B1 (en) 2004-01-23 2005-01-24 Pharmaceutical formulations comprising metformin and a fibrate, and processes for obtaining them

Publications (1)

Publication Number Publication Date
CY1111961T1 true CY1111961T1 (el) 2015-11-04

Family

ID=34639372

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100999T CY1111961T1 (el) 2004-01-23 2011-10-21 Φαρμακοτεχνικες μορφες που περιλαμβανουν μετφορμινη και φιμπρατη και μεθοδοι για ληψη αυτων

Country Status (21)

Country Link
US (2) US20080020046A1 (el)
EP (2) EP1559419A1 (el)
JP (1) JP4740881B2 (el)
CN (1) CN100531722C (el)
AT (1) ATE521338T1 (el)
AU (1) AU2005205930B2 (el)
BR (1) BRPI0507022A (el)
CA (1) CA2553967A1 (el)
CY (1) CY1111961T1 (el)
DK (1) DK1706102T3 (el)
EA (1) EA009773B1 (el)
ES (1) ES2370948T3 (el)
IL (1) IL176903A0 (el)
MA (1) MA28353A1 (el)
NO (1) NO20062792L (el)
PL (1) PL1706102T3 (el)
PT (1) PT1706102E (el)
SI (1) SI1706102T1 (el)
TN (1) TNSN06222A1 (el)
WO (1) WO2005070396A1 (el)
ZA (1) ZA200605882B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
EP2026833A4 (en) * 2006-06-01 2012-05-30 Univ Vermont METHODS FOR INHIBITING CARDIAC PAI-1
CA2672686A1 (en) * 2006-10-12 2008-04-17 Abbott Laboratories Pharmaceutical formulations
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
WO2011154013A1 (en) * 2010-06-10 2011-12-15 Lifecycle Pharma A/S Pharmaceutical composition comprising fenofibric acid
MX363549B (es) * 2010-09-21 2019-03-26 Intekrin Therapeutics Inc Star Composiciones farmacéuticas sólidas antidiabéticas.
WO2013064853A1 (en) * 2011-11-05 2013-05-10 Lupin Atlantis Holdings, S.A. Reduced dose oral pharmaceutical compositions of fenofibrate
WO2013077821A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Homogeneous biguanide composition
WO2014091318A1 (en) * 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
WO2016144766A1 (en) * 2015-03-06 2016-09-15 The University Of North Carolina At Chapel Hill Polymeric metformin and its use as a therapeutic agent and as a delivery vehicle
JP2018507914A (ja) 2015-03-09 2018-03-22 インテクリン・セラピューティクス・インコーポレイテッド 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
WO2022023213A1 (en) * 2020-07-31 2022-02-03 Krka, D. D., Novo Mesto Pharmaceutical formulation of metformin having low content of dimethylamine
WO2023234935A1 (en) * 2022-05-31 2023-12-07 Venkor Corporation Bonded microparticulates preparation and applications thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907792A (en) * 1969-01-31 1975-09-23 Andre Mieville Phenoxy-alkyl-carboxylic acid derivatives and the preparation thereof
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4499289A (en) * 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
EA003101B1 (ru) * 1998-03-19 2002-12-26 Бристол-Майерз Сквибб Компани Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides

Also Published As

Publication number Publication date
CN1909890A (zh) 2007-02-07
BRPI0507022A (pt) 2007-06-05
EA200601215A1 (ru) 2007-02-27
AU2005205930A1 (en) 2005-08-04
ZA200605882B (en) 2009-03-25
DK1706102T3 (da) 2011-12-19
PT1706102E (pt) 2011-12-16
EP1559419A1 (en) 2005-08-03
WO2005070396A1 (en) 2005-08-04
JP2007518773A (ja) 2007-07-12
EA009773B1 (ru) 2008-04-28
AU2005205930B2 (en) 2007-09-20
CN100531722C (zh) 2009-08-26
MA28353A1 (fr) 2006-12-01
ATE521338T1 (de) 2011-09-15
US20080020046A1 (en) 2008-01-24
EP1706102B1 (en) 2011-08-24
PL1706102T3 (pl) 2012-01-31
SI1706102T1 (sl) 2011-12-30
NO20062792L (no) 2006-09-25
CA2553967A1 (en) 2005-08-04
JP4740881B2 (ja) 2011-08-03
IL176903A0 (en) 2006-12-10
ES2370948T3 (es) 2011-12-26
US20110305733A1 (en) 2011-12-15
EP1706102A1 (en) 2006-10-04
TNSN06222A1 (en) 2007-12-03

Similar Documents

Publication Publication Date Title
CY1111961T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν μετφορμινη και φιμπρατη και μεθοδοι για ληψη αυτων
WO2006025979A3 (en) Modulators of nuclear receptors
DE60317159D1 (de) Durch Michael-Additionsreaktion härtbare Zusammensetzung
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
CY1109232T1 (el) Νεα καρβαμυλιωμενη ερο και μεθοδος παραγωγης της
CY1111867T1 (el) Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη
SE0202241D0 (sv) Novel Compounds
TW200626631A (en) Photosensitizer, photosensitive acid generating agent, and photocurable composition
NO20071476L (no) Antidiuretiske midler.
NO345046B1 (no) Oral doseringsform
SE0301009D0 (sv) Novel compounds
DK1506203T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
HK1113790A1 (en) Selurampanel
TW200745039A (en) Isotopically substituted pantoprazole
EA200800324A1 (ru) Новый способ получения солей тиотропия
BRPI0507848A (pt) composição farmacêutica para aplicação oral e método para prepará-la
CY1107028T1 (el) Παραγωγα ινδανυλ-πιπεραζινων μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
NO20050885L (no) Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
DK1388542T3 (da) Anvendelse af hederagenin 3-0-a-L-rhamnopyranosyl((1->2)-[beta-D-glucopyranosyl(1->4)]-a-L-arabinopyranosid eller en ekstrakt fra Pulsatillae radix indeholdende samme som et terapeutisk middel til faste tumorer
EA200801139A1 (ru) Композиция для аэрозольной ингаляции
ATE482187T1 (de) Kontrastmittel
EA200802273A1 (ru) Нейропротективные соединения и их применение